- Home
- INVA
INVA
Innoviva Inc.
as 11-15-2024 4:00pm EST
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 1.3B | IPO Year: | 2004 |
| Target Price: | N/A | AVG Volume (30 days): | 575.7K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.99 | EPS Growth: | 46.55 |
| 52 Week Low/High: | $13.41 - $21.28 | Next Earning Date: | 11-06-2024 |
| Revenue: | $352,745,000 | Revenue Growth: | 21.46% |
| Revenue Growth (this year): | 14.1% | Revenue Growth (next year): | -0.01% |
Latest Innoviva Inc. News
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
INVA: Raising target price to $21.00
Business Wire
4 days ago
Innoviva to Participate in the UBS Global Healthcare Conference
Simply Wall St.
8 days ago
Innoviva Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$1.26 in 3Q 2023)
Associated Press Finance
10 days ago
Innoviva: Q3 Earnings Snapshot
Business Wire
10 days ago
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
Argus Research
11 days ago
INVA: Lowering target price to $20.00
Argus Research
a month ago
INVA: Raising target price to $21.00
Simply Wall St.
2 months ago
Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Compare INVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.